{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:47:11Z","timestamp":1769665631479,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004773","name":"Henan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004773","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.118024","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:11:07Z","timestamp":1753888267000},"page":"118024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design, synthesis, and structure-activity relationship study of novel GLP-1\/GIP\/GCG triple receptor agonists"],"prefix":"10.1016","volume":"298","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3793-1605","authenticated-orcid":false,"given":"Jinhua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanzhen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118024_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118024_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.hjc.2018.11.008","article-title":"GLP-1 receptor agonists and cardiovascular outcome trials: an update","volume":"60","author":"Andrikou","year":"2019","journal-title":"Hellenic J. Cardiol."},{"key":"10.1016\/j.ejmech.2025.118024_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/bs.apha.2022.02.005","article-title":"Cardiovascular effects of GLP-1 receptor agonism","volume":"94","author":"Winquist","year":"2022","journal-title":"Adv. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2025.118024_bib4","first-page":"S125","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in Diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118024_bib5","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/dc21-1113","article-title":"Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes","volume":"45","author":"Wright","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118024_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/clinem\/dgad398","article-title":"Glucagon-like Peptide-1 receptor agonists across the spectrum of heart failure","volume":"109","author":"Ferreira","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10437","key":"10.1016\/j.ejmech.2025.118024_bib7","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ejmech.2025.118024_bib8","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118024_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118024_bib10","first-page":"306","article-title":"Triple-hormone combination retatrutide induces 24% body weight loss","volume":"330","author":"Harris","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.118024_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.170939","article-title":"An update on peptide-based therapies for type 2 diabetes and obesity","volume":"161","author":"Bailey","year":"2023","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118024_bib12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat. Metab."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118024_bib13","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bl\u00fcher","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2025.118024_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1309118","article-title":"Efficacy and safety of mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Nalisa","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2025.118024_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metabol."},{"issue":"23","key":"10.1016\/j.ejmech.2025.118024_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314631","article-title":"Tirzepatide: a systematic update","volume":"23","author":"Forzano","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118024_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118024_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7570\/jomes22067","article-title":"Efficacy and safety of tirzepatide in type 2 diabetes and obesity management","volume":"32","author":"Sinha","year":"2023","journal-title":"J Obes Metab Syndr"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118024_bib19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118024_bib20","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","author":"Aronne","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118024_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118024_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202000052","article-title":"Multiparameter peptide optimization toward stable triple agonists for the treatment of diabetes and obesity","volume":"3","author":"Evers","year":"2020","journal-title":"Adv. Therap."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118024_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2021.12.005","article-title":"Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1\/GIP\/GCG receptor triagonist","volume":"34","author":"Bossart","year":"2022","journal-title":"Cell Metab."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118024_bib24","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1111\/jdi.13896","article-title":"Potential of a glucagon-like peptide-1 receptor\/glucose-dependent insulinotropic polypeptide receptor\/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes","volume":"13","author":"Araki","year":"2022","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.ejmech.2025.118024_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2023.107176","article-title":"A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis-study design and rationale of HM-TRIA-201 study","volume":"130","author":"Abdelmalek","year":"2023","journal-title":"Contemp. Clin. Trials"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118024_bib26","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118024_bib27","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10401","key":"10.1016\/j.ejmech.2025.118024_bib28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118024_bib29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.molmet.2017.02.002","article-title":"Monomeric GLP-1\/GIP\/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice","volume":"6","author":"Jall","year":"2017","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2025.118024_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116725","article-title":"Synthesis and biological evaluation of glucagon-like peptide-1 analogs with the C-terminal helix 3 of albumin-binding domain 3","volume":"62","author":"Zhang","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118024_bib31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118024_bib32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.molcel.2020.09.020","article-title":"Differential GLP-1R binding and activation by peptide and non-peptide agonists","volume":"80","author":"Zhang","year":"2020","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118024_bib33","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41467-022-28683-0","article-title":"Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118024_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41421-024-00700-0","article-title":"Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide","volume":"10","author":"Li","year":"2024","journal-title":"Cell Discov"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T17:53:15Z","timestamp":1769622795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425007895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":34,"alternative-id":["S0223523425007895"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118024","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and structure-activity relationship study of novel GLP-1\/GIP\/GCG triple receptor agonists","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118024"}}